Despite the high prevalence and poor outcome of patients with metastatic lung cancer the mechanisms of tumour progression and metastasis remain largely uncharacterized. Here we modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS 1 and inactivation of the p53 pathway 2 , using conditional alleles in mice 3-5 . Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of Kras LSL-G12D/1 ;p53 flox/flox mice initiates lung adenocarcinoma development 4 . Although tumours are initiated synchronously by defined genetic alterations, only a subset becomes malignant, indicating that disease progression requires additional alterations. Identification of the lentiviral integration sites allowed us to distinguish metastatic from non-metastatic tumours and determine the gene expression alterations that distinguish these tumour types. Cross-species analysis identified the NK2-related homeobox transcription factor Nkx2-1 (also called Ttf-1 or Titf1) as a candidate suppressor of malignant progression. In this mouse model, Nkx2-1 negativity is pathognomonic of high-grade poorly differentiated tumours. Gain-and loss-of-function experiments in cells derived from metastatic and non-metastatic tumours demonstrated that Nkx2-1 controls tumour differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-1-regulated genes, analysis of tumours at defined developmental stages, and functional complementation experiments indicate that Nkx2-1 constrains tumours in part by repressing the embryonically restricted chromatin regulator Hmga2. Whereas focal amplification of NKX2-1 in a fraction of human lung adenocarcinomas has focused attention on its oncogenic function 6-9 , our data specifically link Nkx2-1 downregulation to loss of differentiation, enhanced tumour seeding ability and increased metastatic proclivity. Thus, the oncogenic and suppressive functions of Nkx2-1 in the same tumour type substantiate its role as a dual function lineage factor.
Despite the high prevalence and poor outcome of patients with metastatic lung cancer the mechanisms of tumour progression and metastasis remain largely uncharacterized. Here we modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS 1 and inactivation of the p53 pathway 2 , using conditional alleles in mice [3] [4] [5] . Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of Kras LSL-G12D/1 ;p53 flox/flox mice initiates lung adenocarcinoma development 4 . Although tumours are initiated synchronously by defined genetic alterations, only a subset becomes malignant, indicating that disease progression requires additional alterations. Identification of the lentiviral integration sites allowed us to distinguish metastatic from non-metastatic tumours and determine the gene expression alterations that distinguish these tumour types. Cross-species analysis identified the NK2-related homeobox transcription factor Nkx2-1 (also called Ttf-1 or Titf1) as a candidate suppressor of malignant progression. In this mouse model, Nkx2-1 negativity is pathognomonic of high-grade poorly differentiated tumours. Gain-and loss-of-function experiments in cells derived from metastatic and non-metastatic tumours demonstrated that Nkx2-1 controls tumour differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-1-regulated genes, analysis of tumours at defined developmental stages, and functional complementation experiments indicate that Nkx2-1 constrains tumours in part by repressing the embryonically restricted chromatin regulator Hmga2. Whereas focal amplification of NKX2-1 in a fraction of human lung adenocarcinomas has focused attention on its oncogenic function [6] [7] [8] [9] , our data specifically link Nkx2-1 downregulation to loss of differentiation, enhanced tumour seeding ability and increased metastatic proclivity. Thus, the oncogenic and suppressive functions of Nkx2-1 in the same tumour type substantiate its role as a dual function lineage factor.
We induced lung tumours in mice harbouring a loxP-Stop-loxP Kras G12D knockin allele and both alleles of p53 flanked by loxP sites (Kras LSL-G12D/1 ;p53 flox/flox mice) through intratracheal administration of lentiviral vectors that express Cre-recombinase (Lenti-Cre) 10 . A lentiviral dose was used such that each mouse developed between 5 and 20 lung tumours, lived 8-14 months after tumour initiation and developed macroscopic metastases to the draining lymph nodes, pleura, kidneys, heart, adrenal glands and liver ( Supplementary Fig. 1 ). Because lentiviruses integrate stably into the genome, the integration site was a unique molecular identifier that unambiguously linked primary tumours to their related metastases ( Fig. 1a ). We used linker-mediated polymerase chain reaction (LM-PCR) to determine the genomic sequence directly 39 of the integrated lentiviral genome followed by a specific PCR for the lentiviral integration site (Fig. 1b) . To have samples of sufficient quantity and purity for our analyses, we derived cell lines from primary tumours and metastases. Cell lines were pure tumour cells as determined by recombination of the p53 flox alleles (data not shown). The clonal relationship of these cell lines was established using LM-PCR or Southern blot analysis for the lentiviral genome ( Fig. 1c and data not shown). We termed cell lines derived from verified metastatic primary lung tumours as T Met .
Gene expression profiling was performed on cell lines from 23 lung tumours and metastases (nine metastases, seven T Met primary tumours and seven potentially non-metastatic primary tumours unsupervised consensus clustering 11 , we identified four cell lines from likely non-metastatic tumour samples that had highly concordant gene expression and were separate from all T Met and metastasis (Met) samples ( Supplementary Fig. 2 ). Therefore, we surmised that these could represent non-metastatic primary tumours and classified them as T nonMet . These T nonMet cell lines consistently formed fewer tumour nodules in the liver after intrasplenic injection despite equivalent proliferation rates in cell culture (Fig. 1d , e and Supplementary Fig. 2 ). Significant gene expression alterations distinguished T nonMet from T Met and Met-derived cell lines ( Fig. 1f and Supplementary Table 1 ), many of which were validated by quantitative reverse transcription PCR (qRT-PCR), flow cytometry and western blotting (data not shown). A gene expression signature generated by comparing T nonMet to T Met / Met samples predicted patient outcome in human lung adenocarcinoma gene expression data sets 12, 13 , indicating the possibility of evolutionarily conserved molecular mechanisms of tumour progression (Supplementary Fig. 2 ). Thus, we integrated mouse and human data by comparing the differences in expression between T nonMet and T Met /Met samples with the association of human gene expression and patient survival ( Fig. 2a ). Two genes were particularly notable from this analysis: the NK-related homeobox transcription factor Nkx2-1 and the Nkx2-1 target gene surfactant protein B (Sftpb; Fig. 2a ). Nkx2-1 regulates lung development and is expressed in type II pneumocytes and bronchiolar cells in the adult [14] [15] [16] . Nkx2-1 expression was .10-fold higher in T nonMet samples, and higher NKX2-1 expression in human tumours correlated with longer survival. Of note, NKX2-1 is focally amplified in ,10% of human lung adenocarcinoma, with functional data supporting oncogenic activity in this setting [6] [7] [8] [9] 17 . Conversely, most immunohistochemical analyses of NKX2-1 in this disease suggest an association between NKX2-1-negative tumours and poor patient outcome 17, 18 . Thus, we focused on validating and characterizing the function of this transcription factor in suppressing tumour progression and metastasis.
We confirmed reduced Nkx2-1 messenger RNA and protein in T Met and Met cell lines without evidence of focal genomic loss of this region ( Fig. 2b , Supplementary Fig. 4 and data not shown). Nkx2-1 was consistently downregulated in high-grade poorly differentiated tumours from our mouse model ( Fig. 2c -e and Supplementary Fig. 3 ) as well as in advanced Kras G12D -driven lung adenocarcinomas with p53 R270H or p53 R172H point mutations 4, 19 . Using our LM-PCR assay, we identified three primary lung tumours as metastatic on the basis of the presence of metastases with the same lentiviral integration site ( Fig. 1b and data not shown). These primary tumours each contained poorly differentiated areas that were Nkx2-1 negative (Nkx2-1 2 ) ( Supplementary Fig. 6 ). Interestingly, Nkx2-1 expression was low/ absent in almost all lymph node and distant macrometastases, although some micrometastases were Nkx2-1 1 or Nkx2-1 mixed ( Supplementary  Fig. 3 ). Whether certain micrometastases were seeded by Nkx2-1 1 cells or reverted to an Nkx2-1 1 phenotype due to cues from their new environment is unknown.
In human lung adenocarcinoma 12, 13 the expression of NKX2-1 correlated with a mouse T nonMet gene expression signature ( Supplementary Fig. 3 ). Additionally,theT nonMet signatureanti-correlatedwithanembryonicstemcell signature, supporting the notionthat T Met /Met cells have transitioned to a less differentiated and more stem-like state 20 ( Supplementary Fig. 3 ).
The correlative mouse and human data were consistent with Nkx2-1 being either a marker or a functional regulator of tumour progression. Nkx2-1 expression in a T Met cell line (T Met -Nkx2-1 cells) greatly suppressed tumour formation after intravenous transplantation ( Fig. 3a, b and Supplementary Fig. 5 ). Moreover, of the tumours that formed after injection of T Met -Nkx2-1 cells, many were either Nkx2-1 2 or Nkx2-1 mixed (Fig. 3c ). In general, tumours that continued to express Nkx2-1 were well differentiated, whereas Nkx2-1 2 tumours often displayed solid architecture or areas of poorly differentiated cells ( Fig. 3d and Supplementary Fig.  5 ). Intrasplenic transplantation unveiled a similar diminution of tumour formation by T Met -Nkx2-1 cells ( Supplementary Fig. 5 ). Nkx2-1 expression did not alter proliferation or cell death in cell culture, or affect established tumour proliferation in vivo ( Supplementary Fig. 5 and data not shown), but markedly reduced the ability of these cells to grow in anchorage-independent conditions and initiate tumours after subcutaneous transplantation ( Fig. 3e and Supplementary Fig. 5 ).
To elucidate further the function of Nkx2-1, we knocked down Nkx2-1 in T nonMet cell lines using short hairpin RNA (shRNA; Supplementary  Fig. 7 ). Nkx2-1 knockdown allowed the formation of more liver nodules after intrasplenic injection and more lung nodules after intravenous transplantation ( Fig. 3f ). Nkx2-1 knockdown did not alter proliferation or cell death in cell culture ( Supplementary Fig. 7 ) but enhanced the cells' ability to form colonies under anchorage-independent conditions and tumours after subcutaneous transplantation ( Fig. 3f and Supplementary Fig. 7 ). Re-expression of an shRNA-insensitive Nkx2-1 cDNA (Nkx2-1*) reverted the phenotypic alterations elicited by shNkx2-1, confirming that the effects of shNkx2-1 were specifically due to Nkx2-1 knockdown ( Supplementary Fig. 7 ). Finally, we induced tumours in Kras LSL-G12D/1 ;p53 flox/flox mice with either Lenti-Cre or a lentiviral vector expressing both Nkx2-1 and Cre (Lenti-Nkx2-1/Cre). Expression of exogenous Nkx2-1 limited tumour progression, resulting in fewer tumours of advanced histopathological grades ( Fig. 3g ).
To discover Nkx2-1-regulated genes, we compared gene expression in T nonMet and T nonMet -shNkx2-1 cells. Overlapping this gene list with the genes expressed at different levels in T nonMet versus T Met /Met cells uncovered high priority candidate genes ( Supplementary Fig. 8 ). We elected to focus on Hmga2 given its role in altering global gene expression through the regulation of chromatin structure and its association with embryonic and adult stem-cell states [21] [22] [23] [24] as well as malignant tumours of diverse origins [25] [26] [27] [28] [29] . Hmga2 was de-repressed by Nkx2-1 knockdown in T nonMet cells, and regions of Kras G12D/1 ;p53 D/D tumours that lacked Nkx2-1 expression were almost universally Hmga2 1 (Fig. 4a-c) . Importantly, Nkx2-1 2 areas of known metastatic primary tumours and metastases were also Hmga2 1 ( Supplementary Fig. 9 and data not shown). Additionally, Hmga2 was downregulated in T Met cells after expression of Nkx2-1 cDNA and in T nonMet -shNkx2-1 cells after re-expression of Nkx2-1* (data not shown). correlates with a less differentiated state. a, Cross-species analysis of human lung adenocarcinoma 12 patient outcome (likelihood ratio with the sign from correlation value) versus differential gene expression in murine T nonMet cells. b, Nkx2-1 protein is absent from T Met and Met-derived cell lines. c, d, Nkx2-1 expression is high in well differentiated adenomas and early murine adenocarcinoma (top) but is downregulated in moderately to poorly differentiated advanced carcinomas (bottom). Scale bar 5 50 mm. Upper inset: Nkx2-1 staining. Lower inset: haematoxylin and eosin staining. e, Quantification of Nkx2-1 expression in murine lung tumours relative to tumour grade from most differentiated (atypical adenomous hyperplasia (AAH)) to least differentiated (Poor)).
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Although Hmga2 can be regulated by the Let7 family of microRNAs 21, 25, 30 , Let7 levels, Lin28a expression and Let7 activity were equivalent in T nonMet , T Met and Met cell lines and were unaltered in T nonMet -shNkx2-1 cells ( Supplementary Fig. 10 and data not shown). Hmga2 promoter activity was de-repressed in T nonMet -shNkx2-1 cells and repressed in T Met -Nkx2-1 cells, indicating that expression of Hmga2 in lung adenocarcinoma cells is regulated, at least in part, through differential promoter activity ( Supplementary Fig. 10 ).
We hypothesized that lung adenocarcinomas progress from an Nkx2-1 1 Hmga2 2 to an Nkx2-1 2 Hmga2 1 state. However, metastatic and non-metastatic tumours could be fundamentally distinct at the time of initiation. Hmga2 is highly expressed in embryonic lung but not in any normal adult lung cells, and early after initiation, Kras G12D/1 ;p53 D/D tumours were uniformly Nkx2-1 1 Hmga2 2 (Fig. 4d and Supplementary Fig. 11 ). Kras G12D/1 ;p53-proficient tumours, which maintain their differentiated phenotype and never metastasize even late after tumour initiation 5 , were almost universally Nkx2-1 1 Hmga2 2 ( Supplementary  Fig. 11 ). Poorly differentiated areas of Kras G12D/1 ;p53 D/D tumours with reduced Nkx2-1 expression were never found as in situ lesions and were almost always associated with lower grade Nkx2-1-expressing areas ( Supplementary Fig. 6 ). Finally, we induced Kras G12D/1 ;p53 D/D tumours with a pool of lentiviral vectors that contain nucleotide barcodes. Amplification and sequencing of the lentivirus-encoded barcodes from adjacent low-grade Nkx2-1 1 Hmga2 2 and high-grade Nkx2-1 2 Hmga2 1 areas showed that these areas were clonally related ( Supplementary  Fig. 12 ). Although alternative mechanisms leading to the generation of clonally related but phenotypically distinct tumour cell populations are possible, including the expansion of rare Nkx2-1 2 cells that pre-exist within the tumour, we believe that our data strongly suggest that lung adenocarcinomas undergo a transition from an Nkx2-1 1 Hmga2 2 state to a more aggressive Nkx2-1 2 Hmga-2 1 state. Our data additionally indicate that an Nkx2-1-dependent gene expression program is a key regulator of this transition.
We next analysed the expression of NKX2-1 and HMGA2 in human adenocarcinoma. Although the expression patterns were diverse, two important conclusions could be made. First, tumours of NKX2-1 1 HMGA2 2 and NKX2-1 2 HMGA2 1 phenotypes exist within the spectrum of human lung adenocarcinoma ( Fig. 4e and Supplementary Fig. 10 ). Second, there was a trend towards well-differentiated tumours being NKX2-1 1 HMGA2 2 whereas moderately and poorly differentiated tumours more often exhibited other combinations of these proteins. Most notably, the moderately and poorly differentiated groups contained NKX2-1 2 HMGA2 1 tumours (Fig. 4e ). These results (18) 26 (9) 11 (4) 11 (4) 30 (8) 25 (7) 30 (8) 
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underscore the diversity within this single human tumour type and indicate that our genetically defined model probably represents, at the molecular level, a subset of these tumours.
Next we knocked down Hmga2 in T nonMet -shNkx2-1 cells and found that their metastasis seeding potential was greatly reduced after transplantation ( Fig. 4f and Supplementary Fig. 13 ). Additionally, Hmga2 knockdown in a metastasis-derived cell line reduced its anchorageindependent growth and tumour seeding ability after transplantation (Fig. 4g, h and Supplementary Fig. 13 ). A future challenge will be to understand the molecular mechanism by which Hmga2 controls lung adenocarcinoma metastatic potential. The expansion of Nkx2-1 2 Hmga2 1 regions within primary lung tumours indicates the acquisition of phenotypes that are advantageous to the primary tumours and also increase the probability of metastatic spread.
NKX2-1 can have both oncogenic and tumour suppressive functions in lung cancer, presumably illustrating context-dependent functions within individual tumours of the same type. Lung adenocarcinomas may differ in their cell of origin, mutation spectrum, or gene expression, leading to distinct requirements for continued NKX2-1 expression and different capacity to tolerate or benefit from NKX2-1 downregulation. Our studies uncovered the molecular and cellular basis for the association of NKX2-1 expression with good patient outcome 17, 18 and HMGA2 expression with poor patient outcome 26, 27 . Our results emphasize the power of genetically engineered mouse models of advanced disease, used in conjunction with human studies, to elucidate mechanisms that control cancer progression and metastatic spread. Through this approach we identified one molecular mechanism by which a highly prevalent tumour type can progresses to its malignant state.
METHODS SUMMARY
Mice, tumour initiation and derivation of cell lines. Kras LSL-G12D , p53 flox , p53 LSL-R270H and p53 LSL-R172H mice have been described 3, 5, 19 . Tumours were initiated by intratracheal infection of mice with a lentiviral vector expressing Cre recombinase 10 . The MIT Institutional Animal Care and Use Committee approved all animal studies and procedures. Cell lines were created by enzymatic and mechanical dissociation of individual lung tumours and metastases harvested from mice 8-14 months after tumour initiation. LM-PCR, Southern blotting and gene expression analysis. LM-PCR was performed with forward primers specific for the lentiviral LTR. Southern blotting used a Cre probe and standard methods. RNA was extracted using Trizol, analysed for RNA integrity, and prepared with Affymetrix GeneChip WT Sense Target Labelling and Control Reagents kits, followed by hybridization to Affymetrix GeneChip Mouse Exon 1.0 ST Arrays. Protein and RNA analysis. Western blotting used standard methods and antibodies to Nkx2-1 (Epitomics, Inc.), Hmga2 (BioCheck, Inc.) and Hsp90 (BD Transduction Laboratories) as a loading control. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded 4-mm sections using the ABC Vectastain kit (Vector Laboratories) with antibodies described above. Sections were developed with DAB and counterstained with haematoxylin. Gene expression and knockdown. Nkx2-1 was stably knocked down with a pLKObased lentiviral vector (OpenBiosystems/TRC). MSCV-Puro retroviral vectors were used for stable expression of Nkx2-1 and Nkx2-1* (created with four silent mutations using QuikChange Lightning Site-Directed Mutagenesis (Stratagene)). Hmga2 was stably knocked down with an MSCV-Hygro retroviral vector. Transplantation experiments. For intravenous transplantation, 10 5 cells resuspended in 200 ml PBS were injected into the lateral tail vein. For intrasplenic transplantation 10 5 cells re-suspended in 50 ml PBS were injected. In all graphs each circle represents an individual mouse and the bar represents the mean. Statistical significance was determined using the Student's t-test.
METHODS
Mice, tumour initiation and creation of cell lines. Kras LSL-G12D , p53 flox , p53 LSL-R270H and p53 LSL-R172H mice have been described [3] [4] [5] 19, 31 . Tumours were initiated by intratracheal infection of mice with a lentiviral vector expressing Cre recombinase 10 . The lenti-Cre vector was co-transfected with packaging vectors (delta8.2 and VSV-G; gifts from D. Trono 32 ) into 293T cells using TransIT-LT1 (Mirus Bio). The resultant supernatant was collected at 48 and 72 h. Virus was recovered by ultracentrifugation at 25,000 r.p.m. for 90 min and re-suspended in an appropriate volume of PBS. The MIT Institutional Animal Care and Use Committee approved all animal studies and procedures. Cell lines were created from individual lung tumours and metastases harvested from mice 8-14 months after tumour initiation. Tumours were cut into small pieces and then digested for 30 min at 37 uC in 2 ml of HBSS-free containing trypsin, collagenase IV and dispase in a 15-ml conical tube. Following digestion, 4 ml of Quench Solution (L15 media with 400 ml of FBS and 15 ml of 5 mg ml 21 DNase) was added. Digested tumour samples were then pressed through 40 mm cell strainers (BD Biosciences). Finally, samples were centrifuged at 1,000 r.p.m. for 5 min, re-suspended in culture media (DMEM, 10% FBS, penicillin/streptomycin, glutamine), and plated in a 12well plate. Cells were washed and culture media was changed every day for a week until stable cell lines were formed. In general we were able to derive cell lines from approximately 50% of tumours and metastases without a noticeable difference in the frequency of cell-line generation from metastases from different sites relative to the primary lung tumours. Linker-mediated PCR. Linker-mediated PCR (LM-PCR) was performed essentially as previously described 33 . Annealing two oligonucleotides 59-TAGTCCC TTAAGCGGAG-39 and 59-GTAATACGACTCACTATAGGGCTCCGCTTAA GGGAC-39 created the linker. This linker was ligated to MseI-digested genomic DNA followed by nested PCR using the following primers: forward 1(lentivirus) 59-CTCAATAAAGCTTGCCTTG-39, reverse 1 (linker) 59-GTAATACGACTC ACGATAGGGC-39; forward 2 (lentivirus) 59-CTGTTGTGTGACTCTGGT AAC-39, reverse 2 (linker) 59-AGGGCTCCGCTTAAGGGAC-39.
The PCR products were separated on an agarose gel and specifically amplified bands were gel extracted, cloned into pCRII-TOPO (Invitrogen), and sequenced to identify the exact genomic locus of lentiviral integration. Specific primers were designed in that genomic region to amplify a product from the lentiviral genome to the adjacent somatic genome (lenti-genome band) and also to amplify a product from the other non-integrated allele of that genomic locus (genome-genome band) (see Fig. 1b ). Thus, related tumours can be identified by this three-primer PCR reaction with related tumours having both the lenti-genome and genome-genome bands and unrelated tumours having just the genome-genome band. In general we detected a single lentiviral integrated in each tumour. When we have cloned the exact position of the lentiviral insertion sites we have not yet found an insertion site near a gene of interest. Therefore, it is extremely unlikely that these lentiviruses function as insertional mutagens. Southern blotting. For Southern blotting, 30 mg of genomic DNA was doubly digested with EcoRI and BamHI overnight at 37 uC. 1 ml of enzyme was added in the morning and DNA was digested for an additional hour. The concentration of the digested DNA was determined using a NanoDrop spectrometer. The digested DNA was loaded onto a 0.7% agarose gel and samples were electrophoresed at 30 V for 17-20 h. DNA was transferred onto a positively charged nylon membrane (Hybond-XL, Amersham) overnight and then ultraviolet-crosslinked. A probe for Cre was obtained by PCR amplification from a Cre-containing plasmid using the following primers: forward primer 59-GCTCTAGCGTTCGAACGCAC-39, reverse primer 59-GCTGGCCGGCCCATCGCCATCTTCCAGCAGGC-39.
Probes were labelled using a DECAprime II Random Priming DNA labelling kit, according to the manufacturer's instructions (Ambion). The membrane was hybridized with labelled probe at 65 uC overnight, then washed and exposed overnight on a Phosphoimager Screen, and imaged using a STORM 860 Molecular Imager. Murine gene expression profiling and analysis. Twenty-three samples from murine primary tumour-and metastasis-derived cell lines were collected and RNA was isolated. RNA was extracted using Trizol (Invitrogen), analysed for RNA integrity, and prepared with Affymetrix GeneChip WT Sense Target Labelling and Control Reagents kit, followed by hybridization to Affymetrix GeneChip Mouse Exon 1.0 ST arrays. The resulting image files were pre-processed using the aroma.affymetrix 34 and FIRMA libraries 35 available in the R/Bioconductor software environment 36, 37 . Probe intensities were summarized as expression levels using quantile normalization and RMA.
We applied hierarchical consensus clustering with complete linkage 11 and 1 2 (Pearson's correlation coefficient) as a distance metric, to identify consistently similar expression profiles. The procedure was run over 2,000 iterations with a subsampling ratio of 0.8 on all 23 murine lung tumour samples, and 1,500 variably expressed genes as determined by the median absolute deviation. To identify differentially expressed genes between the T nonMet and T Met /Met samples the significance analysis of microarrays algorithm 38 was applied.
To determine gene expression alterations induced by Nkx2-1 knockdown in T nonMet cells, Affymetrix GeneChip Mouse Exon 1.0 ST Array analyses were performed on 368T1-Control, 368T1-shNkx2-1, 394T4-Control and 394T4-shNkx2-1 cells. The 394T4 samples were run in duplicate using either the Affymetrix GeneChip WT Sense Target Labelling or the Nugene Ovation Systems Target Preparation kits. Thus, a pairwise comparison between the three control and their corresponding shNkx2-1 data sets was used to determine the potential Nkx2-1-regulated genes (Supplementary Table 2 ). We overlapped the gene list generated by the control versus shNkx2-1 comparisons (log 2 . 0.4, paired t-test ,0.08) with the gene list generated from the T nonMet versus T Met /Met samples (log 2 . 0.9, unpaired t-test ,0.02) to identify high priority targets.
Two curated gene sets of proliferation-related genes in humans were obtained from the Molecular Signatures Database (http://www.broadinstitute.org/gsea/msigdb/ index.jsp, cell_proliferation (232 genes, renamed PROLIFERATION_GENESET1) and proliferation_genes (394 genes, renamed PROLIFERATION_GENESET2)). The majority of these human genes mapped to mouse genes, resulting in two proliferation signatures for mice, with 187 and 332 genes respectively. These two signatures were projected on the T Met /Met and T nonMet samples and Nkx2-1 knockdown cell lines data sets. No significant difference in signature scores was observed in T nonMet versus T Met /Met or T nonMet -Control versus T nonMet -shNkx2-1 comparisons as determined by a Student's t-test. Pre-processing of human data set and projection of gene signatures. Human lung adenocarcinoma gene expression analysis used raw data from ref. 12 (364 patients) and ref. 13 (129 patients). These data sets contain patients of all stages. Probes intensities from the Affymetrix U133A platform used in these studies were analysed in a gene-centric fashion 39 and preprocessed using quantile normalization and RMA.
To verify findings from our mouse model, the T nonMet signature and a signature from human embryonic stem cells 20, 40 were projected on the expression profiles of lung adenocarcinoma samples from 364 patients 12 and 129 patients 13 . For a given human adenocarcinoma sample, gene expression values were rank-normalized and rank-ordered. The Empirical Cumulative Distribution Functions (ECDF) of the genes in the gene signature and the remaining genes were calculated. By an integration of the difference between the ECDFs, a statistic was calculated similar to the one used in Gene Set Enrichment Analysis but based on absolute expression rather than differential expression. Details on the method can be found in two papers in which it was applied 41, 42 . The statistic is calculated by replacing the absolute gene expression levels for a given signature G in a single sample S i by their ranks L 5 {r1, r2, r3,…,rN} and rank ordering them. By taking the weighted sum of the difference between the ECDF of the genes in the signature P G and the ECDF of the remaining genes P NG an enrichment score ES(G, S) is obtained:
This calculation was repeated for the T nonMet and ES1 signatures and each sample in the data set. The exponent J adds a slight weight proportional to the outcome value, which is signed. Human lung adenocarcinoma tissue arrays. To determine the expression of NKX2-1 and HMGA2 in human lung adenocarcinoma we stained a tissue microarray (US BioMax, LC1921) for these proteins using the antibodies described above. 43 . The best hairpin sequence targeting Nkx2-1 was shNkx2-1 (TRCN0000086266) 59-CGCCATGT CTTGTTCTACCTT-39. An shRNA targeting luciferase was used as a control. Lentiviral production was performed as described above 44 . The pLKO.1 vectors were co-transfected with packaging vectors (delta8.2 and VSV-G, gifts from D. Trono 32 ) into 293T cells as described above. The resultant supernatant was collected at 48 and 72 h. For cell line infection, 3 3 10 5 cells were plated in a well of a 6-well plate and incubated at 37 uC for $16 h. Cells were incubated with equal volumes of virus and complete media for at least 24 h, at which point fresh media was added. Puromycin (16 mg ml 21 for 368T1, 32 mg ml 21 for 394T4) was also added at this point. Cells were collected for isolation of RNA and protein 2 weeks after infection with the shRNA viruses. MSCV-driven ecotropic retroviral vectors were made by transfecting 293T cells with equal amount of the MSCV vector and pCLEco package vector 45 .
MSCV-Puro (control): retroviral expression vector driving the cDNA of interest off the MSCV LTR and puromycin resistance off the PGK-promoter (Clontech). The empty vector was used as a control.
MSCV-Nkx2-1/Puro: Nkx2-1 cDNA was PCR amplified using the following primers: forward 59-GAGTTAACCCACCATGTCGATGAGTCCAAAGCAC-39, reverse 59-CTGAATTCTCACCAGGTCCGACCATAAAG-39, followed by cloning into pCRII-TOPO (Invitrogen), sequence verification, digestion and ligation into MSCV-Puro.
MSCV-Nkx2-1*/Puro: an shNkx2-1 insensitive Nkx2-1 cDNA was created by engineering four silent mutations using QuikChange Lightning Site-Directed Mutagenesis (Stratagene) and the following primers: 59-GGTCCGACCATAA AGCAAAGTGGAGCAGGACATGGCGCCATAGTCCGAG-39 and 59-CTCGG ACTATGGCGCCATGTCCTGCTCCACTTTGCTTTATGGTCGGACC-39 followed by sequence verification and cloning into the MSCV-Puro retroviral expression vector.
MSCV-Hygro (control): a hygromycin-resistant retroviral expression vector was created by swapping the hygromycin-resistance gene for the puromycinresistance gene in MSCV/LTRmiR30-Puro-IRES-GFP 46 . The empty vector was used as a control.
MSCV-shHmga2/Hygro: shRNAs were designed using http://www.biopredsi.org/ start.html and resources available through G. Hannon's laboratory at Cold Spring Harbour Laboratories (http://katahdin.cshl.org/siRNA/RNAi.cgi?type5shRNA). Five sequences within Hmga2 were cloned into the miR30 sequence and tested for effective knockdown. The oligonucleotides were amplified, digested and cloned into MSCV-Hygro. The correct sequence was verified by sequencing the final vector. The following oligonucleotide gave the best Hmga2 knockdown: shHmga2 (NM_010441-1375) 59-TGCTGTTGACAGTGAGCGAAAGGACTATATTAATCACTTTTAGT GAAGCCACAGATGTAAAAGTGATTAATATAGTCCTTCTGCCTACTGCCT CGGA-39. This was used to knock down Hmga2 in the T nonMet -shNkx2-1 cells.
pLKO.shHmga2: to knock down Hmga2 in a metastasis-derived cell line (482N1) pLKO.1 lentiviral vectors targeting Hmga2 were obtained from The RNAi Consortium 43 . The best hairpin sequence targeting Hmga2 was shHmga2 (TRCN0000265760) 59-GAAACTTATCAAGACGATTAA-39. An shRNA targeting luciferase was used as a control. Lentiviral production was performed as described above 44 . Cell culture and transplantation assays. To assess proliferation, 100,000 cells were plated in each well of a 6-well plate. Eighteen hours later the sub-confluent cells were labelled with 10 mm BrdU for 1 h followed by anti-BrdU staining using the BD APC flow kit following the manufacturer's instructions. For anchorageindependent growth assays, cells were plated in triplicate or quadruplicate in 35 mm tissue culture dishes in 0.4% agar in culture media on top of a layer of 0.8% agar with culture media. For T nonMet and T nonMet -shNkx2-1 3 3 10 4 cells were plated. For T Met , T Met -Nkx2-1, Met and Met-shHmga2 1 3 10 4 cells were plated. Cells were allowed to grow at 37 uC for 2-3 weeks. Colonies were stained with 0.2% crystal violet at room temperature for 30 min and subsequently destained with water for several days. Once the colonies were visible by eye, they were counted using a microscope. A colony was defined as anything containing more than 10 cells.
For intravenous injection, recipient mice were injected with 10 5 cells resuspended in 200 ml PBS in the lateral tail vein. Intravenously injected mice were analysed 3-4 weeks after injection. Quantification of lung tumour nodules was performed by counting all the visible surface tumours on the large left lung lobe.
Intrasplenic injection of 10 5 cells re-suspended in 50 ml HBSS was performed as described 47, 48 . Briefly, mice were anaesthetized with avertin (0.5 mg g 21 intraperitoneally) before surgery. Once the animals were under deep anaesthesia the fur was removed from the left abdominal and thoracic areas using surgical clippers. The area was disinfected with Betadine and 70% ethanol. The spleen was exposed through a small incision. Cells were injected into the spleen with a single injection using an insulin syringe. Cells were given 10 min to travel through the vasculature to the liver, after which the entire spleen was removed to prevent the formation of a large splenic tumour mass. To remove the spleen, a dissolvable 4-0 suture was tied snugly around the base of the spleen including the major splenic vasculature and the spleen was removed. The muscle wall was closed with 4-0 dissolvable sutures and the skin incision closed with sterile 7-mm wound clips (Roboz). Intrasplenically injected mice were analysed 3-4 weeks after injection. Quantification of liver tumour nodules was performed by counting all the visible surface tumours under a dissecting scope.
For T Met and T Met -Nkx2-1 subcutaneous injection, recipient mice were injected with 10 5 cells re-suspended in 50 ml PBS under the skin on their hind flank. Subcutaneously injected mice were analysed 10 weeks after injection. Both the presence of a tumour nodule and the weight of the resulting tumour were scored. For T nonMet and T nonMet -shNkx2-1 subcutaneous injections, recipient mice were injected with 10 6 , 10 5 , 10 4 , or 10 3 cells re-suspended in 50 ml PBS under the skin on each of their hind flanks. Subcutaneously injected mice were analysed 4 weeks after injection. Both the presence of a tumour nodule and the weight of the resulting tumour were scored.
For all transplants recipient mice were 129/Bl6 F 1 mice (Jackson Laboratories) except in experiments with MSCV-shHmga2/Hygro and MSCV-Hygro (control), which necessitated the use of immunocompromised Rag2 2/2 recipient mice, due to an apparent immunogenicity of the hygromycin-resistant gene. Creation of dual promoter lentiviral vector for Nkx2-1 cDNA expression. To determine the effect of continued exogenous Nkx2-1 expression on lung tumour progression we created a lentivural vector that expressed both Nkx2-1 and Crerecombinase. This vector had the Ubc promoter driving Nkx2-1 cDNA and the PGK promoter driving Cre expression (pLL3.Ubc-Nkx2-1;Pgk-Cre). A lentivirus expressing Cre alone (PGK-Cre) was used as a control. Virus was produced and titred as described above. Cohorts of Kras LSL-G12D ;p53 flox/flox mice were infected with each lentiviral vector. Tumour grade was determined 18 weeks after tumour initiation. DNA copy number data set. DNA copy number analysis was performed on 25 lung adenocarcinoma cell lines using the Illumina Genomic DNA Sample Preparation Kit (unpublished data set). Single-end 35 nucleotide reads were generated using the Illumina Genome Analyser IIx. Reads were aligned to the July 2007 build of the Mus musculus genome (NCBI37/mm9) with MAQ and filtered for mapping quality .30. Copy number ratios were calculated as the number of normalized reads from the tumour sample, divided by the number of normalized reads from the ref-erence129/SVJ strain. Boundaries of copy number changes were identified using change point analysis 49 . DNA copy number was visualized using the Broad Institute's Integrated Genome Viewer (http://www.broadinstitute.org/igv). Hmga2 promoter assays. To assess the activity of a conserved promoter of the Hmga2 gene, a 2.83-kb fragment of genomic DNA (NCBI37/mm9:chr10:119913940-119916769) was PCR amplified and ligated into the multiple cloning site of the pGL3 firefly luciferase vector (Promega). Tumour cells were transfected with the Hmga2-luc construct and a thymide-kinase promoter driven Renilla luciferase construct using Attractene (Qiagen). Luciferase activity was determined using the Dual Luciferase Reagents (Promega) and Hmga2 activity was normalized to the Renilla luciferase activity. An empty pGL3 construct was used as a control and the Hmga2-luciferase values were additionally normalized to the values obtained using the empty pGL3 construct.
